Integrated DNA Technologies and SGI-DNA Broaden Their Collaboration to Provide Synthetic DNA Products Up to 2 Mbp
Published: Feb 28, 2013
IDT is the world’s leader in custom oligonucleotide synthesis and SGI-DNA is a newly formed subsidiary of Synthetic Genomics, Inc. (SGI), which focuses on genomic-driven solutions to a variety of global needs.
In February of 2012, IDT and SGI began to co-manufacture, commercialize, and market small synthetic gene products of up to 5 kb. IDT also launched its gBlocks™ Gene Fragments product line, for use in combination with SGI’s proprietary DNA technologies, including Gibson Assembly™, to assemble small gene constructs efficiently. gBlocks™ Gene Fragments have already revolutionized synthetic biology applications by substantially lowering DNA synthesis costs and making DNA assembly more efficient and reliable.
IDT and SGI-DNA are now extending this collaboration to manufacture and co-brand cloned synthetic DNA constructs up to 2 Mbp, and to make them available through IDT. This product offering has not been available until today and will make possible new applications including metabolic and whole genome engineering through de novo DNA synthesis. SGI-DNA will manufacture and become IDT’s exclusive supplier of the larger constructs. The two companies will also work together on the launch of an expanded IDT gBlocks Gene Fragments offering, expected later in 2013.
Dr. Joseph Walder, IDT’s Founder and Chief Executive Officer, noted, “By joining forces, IDT and SGI-DNA will enable the research community by providing a complete solution, from short genes to very large synthetic constructs, at prices and with delivery times simply unavailable in the market today.” “Enabling new and better research has always been the essence of IDT’s mission, so it’s the perfect fit.”
“Over the last year, we have grown our in-house gene synthesis business, and effectively worked together with IDT to co-manufacture and co-market smaller synthetic gene products. This is the natural next step in that collaboration,” agreed J. Craig Venter, Ph.D., SGI’s Founder and Chief Executive Officer. He continued, “We are excited about what we’ll accomplish through the combination of SGI-DNA’s unique expertise with large, complex gene products and IDT’s experience in manufacturing and delivering small DNA products to researchers around the globe.”
SGI is also announcing the official launch of SGI-DNA, which will be responsible for all aspects of the development, manufacture, and commercialization of SGI’s synthetic DNA business.
IDT and SGI-DNA did not disclose the financial details of their arrangement. For more information about how to order IDT/SGI-DNA products, please visit https://www.idtdna.com/pages/products/genes/custom-gene-synthesis.
For more information please visit www.idtdna.com. Follow us on twitter @idtdna for real-time updates and insights.
Integrated DNA Technologies, Inc. (IDT) is the largest supplier of custom synthetic nucleic acids in the world, serving the areas of academic research, biotechnology, clinical diagnostics, and pharmaceutical development. IDT's primary business is the manufacture of custom primers, probes, and genes for research and diagnostic applications. Today, IDT synthesizes and ships an average of 36,000 custom oligos per day to more than 86,000 customers worldwide. IDT’s manufacturing locations include facilities in Coralville, Iowa; San Diego, Calif.; Leuven, Belgium; and Singapore. For more information, visit www.idtdna.com.
SGI-DNA, a wholly owned subsidiary of Synthetic Genomics, Inc. (SGI) founded in 2013 and headquartered in La Jolla, CA, provides differentiated synthetic DNA solutions to leading organizations with demands for large and/or complex DNA constructs. Building on the scientific breakthroughs from leading scientists J. Craig Venter, Hamilton Smith, Clyde Hutchison, Dan Gibson and their teams, SGI-DNA utilizes unique and proprietary DNA synthesis technologies from SGI to produce synthetic genes, genetic pathways, and whole genomes quickly and cost-effectively. SGI-DNA is responsible for all commercial aspects of SGI’s synthetic DNA business and focuses on strategic business relationships with both academic and commercial researchers. For more information, visit www.sgidna.com.
About Synthetic Genomics Inc.
SGI, a privately held company founded in 2005, is dedicated to developing and commercializing genomic-driven solutions to address a wide range of global challenges. The company is focused on several key research and business programs including: developing new synthetic DNA products and technologies through SGI-DNA, algae biofuels, new and improved food and nutritional products, and clean water technology. SGI is also involved in synthetically derived vaccine development through Synthetic Genomic Vaccines Inc. (SGVI), a business unit co-founded with the J. Craig Venter Institute; and in developing sustainable crops such as castor and sweet sorghum and agricultural products through AgraCast, a company co-founded with Plenus S.A. de C.V. For more information go to: www.syntheticgenomics.com
Media Contact for SGI and SGI-DNA